Articles about Central Drugs Standard Control Organization (CDSCO)

India is set to begin the phase-2 trials of the world's first one-shot pneumococcal vaccine for adults soon.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday.

Johnson & Johnson has withdrawn its proposal seeking an accelerated approval of its COVID-19 vaccine, Janssen, in India, the country's drug regulator said.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses.

A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.

In a bid to extend the country's vaccination drive to include people below 18 years, an expert panel on Tuesday recommended Hyderabad-based Bharat Biotech's COVID-19 vaccine COVAXIN for phase 2/3 clinical trials on children and adolescents aged two to 18 years.

India's drug regulator will make a decision on applications seeking approval for restricted emergency use of foreign-produced vaccines within three working days from the date of submission, the government said on Thursday.

An expert panel, Central Drugs Standard Control Organisation, (CDSCO) on Tuesday recommended granting permission for conducting the Phase I clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.

Serum Institute of India's (SII) chief Adar Poonawalla today wished everyone a happy new year along with a great announcement.

A government-appointed panel on Saturday recommended emergency-use authorization (EUA) to the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech.

India recorded less than 300 deaths linked to coronavirus every day between last Thursday and today, the government said.

In a development that will soothe the coronavirus-battered nation, the Central Drugs Standard Control Organization (CDSCO) panel on Friday gave approval to the vaccine developed by the University of Oxford and British-pharma giant AstraZeneca.

After the meeting on Wednesday to judge the emergency use authorization applications of coronavirus vaccine developers remained without a conclusion, the subject expert committee (SEC) will meet again today.

The United Kingdom on Wednesday approved the vaccine developed by Oxford University and the British-Swedish pharmaceutical company AstraZeneca, giving the vaccine an endorsement that will likely be considered by Indian drug regulators.

The coronavirus vaccine, developed by the University of Oxford and AstraZeneca, is likely to get approval from the Indian government for emergency use by next week, two people privy to the development told Reuters.

With the coronavirus vaccine trials being conducted by Serum Institute of India (SII) being shrouded in controversy after a participant complained of an "adverse reaction," the Centre on Tuesday said there's no need to stop the process.

Hyderabad-based pharmaceutical firm Bharat Biotech is expecting to launch its coronavirus vaccine candidate, COVAXIN, by June next year.

India's drug regulator has refused to allow a large scale clinical trial of Russia's Sputnik V COVID-19 vaccine.

Last night, Amazon expressed discontent over Future Group's deal to sell its businesses to Reliance Retail and issued the former a legal notice.

Sputnik V, the COVID-19 vaccine developed and approved by Russia, has shown side effects in some trial volunteers.

In a major development, Hyderabad-based pharma company Dr. Reddy's Laboratories has partnered with the Russian Direct Investment Fund (RDIF) to source their Sputnik V COVID-19 vaccine for India.

On Tuesday, Russia announced what it claims is the first COVID-19 vaccine, developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Moscow.

The Serum Institute of India (SII) has gotten the approval to conduct phase 2 and 3 human clinical trials of the COVID-19 vaccine candidate developed by Oxford University.

Remdesivir has been approved by India's top drug regulator for "restricted emergency use" on COVID-19-infected adults and children.

In a major development, Pune-based molecular diagnostics company Mylab Discovery Solutions has been given the go-ahead to develop testing kits for the novel coronavirus disease (COVID-19).

The Supreme Court yesterday sought the Center's response on a plea alleging that "faulty" and "deadly" hip implants, made by US-based pharma major Johnson & Johnson (J&J), have been fitted into the bodies of 14,525 Indian patients, termed as "medical negligence" by an expert committee.

The Union Health Ministry has invited suggestions for renaming the country's drug regulator CDSCO in line with its expanded roles.

To ensure the quality of drugs, Health Ministry is planning to make companies, which market and promote medicines, responsible for any violation of drug regulations like manufacturers.

Health Ministry has banned over-the-counter (OTC) sale of 14 steroid-based creams and ointments by bringing them under the Schedule H of the Drugs and Cosmetics Rules, 1945.

Bengaluru's Bellandur Lake frothing has turned the Centre's attention to high phosphorus content in laundry detergents, bars, and industrial cleaners.

Sources have stated that India's Central Drug Standard Control Organization (CDSCO) is in the process of reviewing the US FDA's ban on certain compounds used in anti-bacterial soaps.

The US Food and Drug Administration declared a final command meant to protect the people from the chemicals in antibacterial soaps.